CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
PK of APG-2575 in combination with Azacitidine in the patients with AML/MPAL or MDS/CMML. The study consists of dose escalation (Part I) and...
Phase 1, Phase 2
Charlotte, North Carolina, United States and 8 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed th...
Phase 1
Charlotte, North Carolina, United States and 30 other locations
This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination with hypomethylating agents (HMA) by evaluating MBG453 i...
Phase 2
Charlotte, North Carolina, United States and 27 other locations
subjects with previously treated or untreated with high risk factor acute myeloid leukemia (AML). Venetoclax and ...
Phase 1
Charlotte, North Carolina, United States and 3 other locations
cytotoxic chemotherapy in induction-eligible patients with acute myeloid leukemia.This study involves the following:* Vene...
Phase 2
Charlotte, North Carolina, United States and 8 other locations
LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid...
Phase 1, Phase 2
Charlotte, North Carolina, United States and 13 other locations
drug cusatuzumab added to venetoclax and azacitidine works to treat acute myeloid leukemia (AML) compared to vene...
Phase 2
Charlotte, North Carolina, United States and 17 other locations
standard of care treatments for patients with relapsed/refractory acute myeloid leukemia will be examined with the followi...
Phase 1
Charlotte, North Carolina, United States and 13 other locations
Some people with MDS have a risk of the disease progressing to acute myeloid leukemia (AML), and a risk of death ...
Phase 3
Charlotte, North Carolina, United States and 221 other locations
This is a phase I/II Study of Nivolumab in Combination with 5-azacytidine in pediatric patients with relapsed/refractory acute myeloid...
Phase 1, Phase 2
Charlotte, North Carolina, United States and 11 other locations
Clinical trials
Research sites
Resources
Legal